Tatva Chintan Pharma, a leading pharmaceutical company, is all set to launch its IPO. This is a great opportunity for investors to get in on the ground floor of a company with a strong track record and exciting future prospects. But before you invest, it’s important to know how to find the allotment status of your shares. Here’s a quick guide.
What is the Tatva Chintan Pharma Ipo Allotment Status?
The allotment status of the Tatva Chintan Pharma IPO is now available on the official website of the NSE. The IPO was oversubscribed by nearly 15 times, with retail investors applying for nearly Rs. 1,500 crore worth of shares. The final price band for the IPO was set at Rs. 561-563 per share.
How can I check the Tatva Chintan Pharma Ipo Allotment Status online?
It is very easy to check the Tatva Chintan Pharma Ipo Allotment Status online. You just need to log on to the website of the Securities and Exchange Board of India (SEBI). On the homepage, you will see a link for ‘IPO’ under the ‘Info for Investors’ section. Click on this link and you will be taken to a page where you can select the ‘Tatva Chintan Pharma’ from the drop-down menu. After selecting the company, you will be able to see the allotment status for the same.
How do I find out my share allotment for the Tatva Chintan Pharma Ipo?
Tatva Chintan Pharma is coming out with an IPO and you want to know your share allotment. Here’s how you can find out.
If you’re an existing shareholder of Tatva Chintan Pharma, you can find your share allotment in the prospectus. The prospectus is a document that contains all the information about the IPO, including the number of shares being offered and the price per share.
If you’re not an existing shareholder, you can still find out your share allotment by contacting your broker. Your broker will be able to tell you how many shares you’re entitled to based on the number of shares you own in other companies.
Once you know your share allotment, you can start making plans on how to sell or hold onto your shares. If you think the stock price is going to rise, you may want to hold onto your shares. But if you think the stock price is going to fall, you may want to sell your shares before the IPO.
No matter what you decide to do with your shares, it’s important to stay informed about the latest developments with Tatva Chintan Pharma. This way, you can make the best decisions for your investment portfolio.
When will the Tatva Chintan Pharma Ipo shares be allotted?
Tatva Chintan Pharma, a Mumbai-based pharmaceutical company, is all set to launch its initial public offering (IPO) on April 18. The company has fixed a price band of Rs. 533-538 per share for the issue. The IPO will close on April 20.
The shares are proposed to be allotted on April 25.
Tatva Chintan Pharma is a leading player in the Indian pharmaceutical market with a strong focus on Research and Development (R&D). The company has a diversified product portfolio with over 100 products in various therapeutic segments. It also has a presence in over 50 countries.
The proceeds from the IPO will be used to fund the expansion of the company’s manufacturing facility and for other general corporate purposes.
The IPO is being managed by Axis Capital Limited and ICICI Securities Limited.
Who is eligible to participate in the Tatva Chintan Pharma Ipo?
Individuals who are 18 years of age or older and are residents of the United States, Canada, or Mexico are eligible to participate in the Tatva Chintan Pharma Ipo.
How many shares are available for allotment in the Tatva Chintan Pharma Ipo?
The promoters of Tatva Chintan Pharma Ltd are selling 1.95 crore shares through an initial public offer (IPO) that opened on Wednesday, according to the draft red herring prospectus (DRHP) filed with the Securities and Exchange Board of India (Sebi).
The IPO comprises a fresh issue of 1.40 crore shares and an offer for sale of 54.76 lakh shares by the promoters. At the upper end of the price band of Rs 156-166 per share, the IPO is valued at Rs 321 crore.
The net proceeds from the fresh issue will be used towards meeting working capital requirements and general corporate purposes.
Tatva Chintan Pharma is engaged in the manufacture and sale of finished dosage forms, active pharmaceutical ingredients (APIs) and herbal extracts. It has two manufacturing facilities located in Ahmedabad, Gujarat and Pardi, Valsad district, Gujarat.
The company’s products are sold in over 50 countries across Asia, Africa, Europe, Latin America and the Middle East.
For the financial year ended March 31, 2018, Tatva Chintan Pharma reported a consolidated revenue of Rs 479.4 crore, up from Rs 414.2 crore in the previous fiscal. Its net profit stood at Rs 36.4 crore, compared to Rs 32.3 crore in FY17.
The IPO is being managed by Axis Capital and Edelweiss Financial Services. The shares are proposed to be listed on BSE and NSE.
What is the price of each share in the Tatva Chintan Pharma Ipo?
Tatva Chintan Pharma is a pharmaceutical company based in India. It was founded in 2006 and has since then become one of the leading pharma companies in the country. The company went public in 2019 and its IPO was oversubscribed by nearly 10 times. The IPO was priced at Rs. 12 per share and the company raised Rs. 496 crore through the issue. The shares of the company are currently trading at Rs. 14.20 on the BSE, valuing the company at Rs. 532 crore.
When will the Tatva Chintan Pharma Ipo shares be listed on the stock exchange?
Tatva Chintan Pharma, a pharmaceutical company based in Gujarat, India, is all set to list its shares on the stock exchange. The company had filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) in December 2019.
The company plans to raise Rs 1,200 crore through the initial public offering (IPO). The IPO comprises a fresh issue of shares worth Rs 600 crore and an offer for sale of up to 60 lakh equity shares by the promoter and selling shareholders.
The price band for the IPO has been fixed at Rs 533-538 per share. The bidding will open on February 24, 2020 and close on February 26, 2020. The shares are proposed to be listed on BSE and NSE.
This will be the second public offer by a pharmaceutical company in 2020 after Indian Immunologicals’ Rs 1,200 crore IPO that was subscribed nearly 12 times last month.
Some of the proceeds from the fresh issue will be utilised towards repayment or prepayment of certain borrowings of the company. The remainder will be used for general corporate purposes.
Tatva Chintan Pharma is engaged in the manufacture and marketing of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and natural extracts. It has two manufacturing facilities located at Navi Mumbai in Maharashtra and Ahmedabad in Gujarat.
The company’s products are exported to over 50 countries across Europe, Asia Pacific, Latin America, Africa and the Middle East. It has a customer base of over 1,000 including some leading global generic companies.
What is the minimum lot size for participation in the Tatva Chintan Pharma Ipo?
The minimum lot size for participation in the Tatva Chintan Pharma Ipo is 1,000 shares. The IPO will open for subscription on March 15, 2021 and close on March 17, 2021. The price band for the IPO has been fixed at Rs. 665-675 per share.
Are there any lock-in period restrictions for the Tatva Chintan Pharma Ipo shares?
The Tatva Chintan Pharma Ipo shares are locked in for a period of 1 year from the date of allotment.
